Liver Disease Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Liver Disease Diagnostics Market is segmented by Diagnosis Technique (Liver Biopsy, Imaging Tests, Liver Function Tests, and Endoscopy), End User (Hospitals, Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Liver Disease Diagnostics Market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Liver Disease Diagnostics Market is expected to register a CAGR of 5.8% over the forecast period, 2022-2027.

COVID-19 virus may be associated with abnormalities in liver tests, usually in more severe cases. Although the impact of COVID-19 on individuals with hepatitis B or C is still unknown, these patients may be more susceptible to negative effects. The transplant waiting list has also been significantly impacted by the pandemic. Angiotensin-converting enzyme 2 (ACE2) is involved in the binding of SARS-CoV-2 and its internalization into target cells. Since biliary and liver epithelial cells have ACE2, the liver could be a target for infection. For instance, in November 2021, the American Association for the Study of Liver Disease stated that the incidence of elevated serum liver biochemistries in hospitalized patients with COVID-19 ranges from 14% to 83%. This has created a significant demand for various liver function tests globally to check and manage liver enzyme levels.

The growing prevalence of liver diseases and advancements in diagnostics are primarily driving the market growth. Furthermore, excessive alcohol consumption, coupled with rising awareness about early diagnosis of liver diseases around the world, is anticipated to boost the market growth. The American Cancer Society predicts that, in 2022, there will be 41,260 new instances of primary liver cancer and intrahepatic bile duct cancer (28,600 in men and 12,660 in women), and 30,520 people will die from these malignancies (20,420 men and 10,100 women). Additionally, according to a 2021 publication from the American Liver Foundation, non-alcoholic fatty liver disease affects around 25% of adults in the United States (NAFLD). In 2020, JHEP Innovation in Hepatology published that between 2015 to 2030, the incidence of non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) in the United States is predicted to rise by 137%. Accurate diagnosis is a challenge faced by patients with rare liver diseases. To avoid this, novel approaches to liver disease diagnosis have been developed. The aforementioned factors, such as the increase in liver disorders and new diagnostic techniques, will fuel the market's rise in liver disease diagnostics over the forecast period.

Alcohol abuse, a major cause of serious noncommunicable diseases such as liver cirrhosis, is another contributing factor. According to the Centers for Disease Control and Prevention update in 2020, the number of alcoholic liver disease deaths in the United States is 29,505. Alcohol-related liver disease can be diagnosed by a history of alcohol abuse along with laboratory or radiologic abnormalities and liver biopsy. However, the high cost of the development of testing technologies is expected to impede market growth over the forecast period.

Scope of the Report

As per the scope of the report, diagnostic procedures for liver disease aid in determining the liver's condition. When liver cells die, their chemical constituents are discharged into the bloodstream, which aids in the detection of liver illness through liver function tests. The Liver Disease Diagnostics Market is segmented by Diagnosis Technique (Liver Biopsy, Imaging Tests, Liver Function Tests, and Endoscopy), End User (Hospitals, Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Diagnosis Technique
Liver Biopsy
Imaging Tests
Liver Function Tests
Endoscopy
By End User
Hospitals
Laboratories
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Imaging Tests Anticipated to have Lucrative Growth

The imaging segment has significant growth in the market due to its high specificity when compared with other diagnostic techniques. Ultrasonography, radionuclide scanning, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography, and surgical cholangiography are imaging procedures for the liver, gallbladder, and biliary tract. The key players in the market for liver imaging diagnostics are partnering with each other to increase awareness and advance the early diagnosis of various liver diseases. For instance, in June 2022, Echosens and Novo Nordisk collaborated on the adoption of non-invasive diagnostic tests for non-alcoholic steatohepatitis (NASH) and work together to increase awareness of the disease and the importance of early diagnosis and management. By 2025, the firms hope to have doubled the rate of diagnoses for those with advanced to severe NASH. Additionally, in 2022, the National Library of Medicine published that gradient recalled echo (GRE) MRI is the most accurate imaging method to detect the existence and severity of hepatic steatosis. These advancements in imaging technology could improve the accuracy of diagnosing liver disease and contribute to market expansion.

Most Common Causes of Chronic Liver Disease

North America is Anticipated to Dominate the Market

North America is expected to dominate the market due to high research and collaboration for clinical trial studies and an increase in the incidences of liver disease in the region. According to the Canadian Liver Foundation in In 2020, non-alcoholic fatty liver disease is the most common liver disease, affecting over 7 million people and liver cancer is the fastest rising and deadliest form of cancer in Canada. Additionally, the American Association for the Study of Liver Diseases article published in January 2022, states that the incidence of non-alcoholic fatty liver disease (NAFLD) is highest in Mexican-origin (MO) adults compared to all adults of Hispanic origin and all racial and ethnic subpopulations in the United States. Furthermore, in November 2021, Perspectum and HepQuant collaborate to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services, which will enable the clinical trials of liver disease to receive both imaging and function testing from Perspectum. These collaborations and the usage of various testing methods in clinical trials help in liver disease diagnosis, thereby boosting the overall market demand.

Liver Disease Diagnostics Market

Competitive Landscape

The liver disease diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The major companies operating in the industry are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Siemens Healthcare GmbH, BioMerieux SA, Quest Diagnostics Incorporated, Biosino Bio-Technology and Science Inc, and Echosens.

Recent Development

  • In March 2022, Echosens launched an affordable, cost-effective tool for screening liver health, FibroScan GO in the United Kingdom.
  • In January 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) Test in the United States, the first and only prognostic blood test granted De Novo marketing authorization to assess disease progression in non-alcoholic steatohepatitis (NASH) patients.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Alcohol Consumption

      2. 4.2.2 Increase in Prevalence of Liver Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Diagnostic Test

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Diagnosis Technique

      1. 5.1.1 Liver Biopsy

      2. 5.1.2 Imaging Tests

      3. 5.1.3 Liver Function Tests

      4. 5.1.4 Endoscopy

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Laboratories

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott

      2. 6.1.2 F. Hoffmann-La Roche Ltd.

      3. 6.1.3 Thermo Fisher Scientific Inc.

      4. 6.1.4 Randox Laboratories Ltd.

      5. 6.1.5 Boston Scientific Corporation

      6. 6.1.6 Laboratory Corporation of America Holdings

      7. 6.1.7 Siemens Healthcare GmbH

      8. 6.1.8 BioMerieux SA

      9. 6.1.9 Quest Diagnostics Incorporated

      10. 6.1.10 Biosino Bio-Technology and Science Inc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Liver Disease Diagnostics Market market is studied from 2019 - 2027.

The Global Liver Disease Diagnostics Market is growing at a CAGR of 5.8% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

F. Hoffmann-La Roche Ltd, Echosens, Siemens Healthcare GmbH, Boston Scientific Corporation, Thermo Fisher Scientific Inc. are the major companies operating in Global Liver Disease Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!